Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 3:15 p.m. ET in Room 7.03 of the Millennium Broadway Hotel in New York.

Dr. Missling will provide an overview of the Company’s business and will be available to participate in one-on-one meetings with investors attending the conference.

Qualifying investors can register for free admission through the online form for the Rodman & Renshaw conference:

https://www.meetmax.com/sched/event_20174/investor_reg_new.html?event_id=20174&cmd=register.

Conference attendees are invited to contact Anavex in advance at ir@anavex.com to discuss meetings with Dr. Missling.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug candidates.  ANAVEX 2-73, a drug candidate developed to treat Alzheimer’s disease through disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg.  Conducted pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.  Anavex is a publicly traded corporation quoted as AVXL.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties.  Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information

Anavex Life Sciences Corp.
Research & Business Development
Email: info@anavex.com

Shareholder & Media Relations
Toll-free: 1-866-505-2895
Outside North America: +1 (416) 489-0092
Email: ir@anavex.com
www.anavex.com